Scripps Research expands drug repurposing efforts for COVID-19

By The Science Advisory Board staff writers

April 16, 2020 -- Scripps Research has pivoted its drug repurposing collection ReFRAME to find antiviral compounds effective against the novel coronavirus.

Researchers from Scripps' drug development division Calibr will work with scientists from around the world to look for compounds from individual drugs or drug combinations that could treat patients with COVID-19. It is part of an accelerator launched by the Bill & Melinda Gates Foundation to develop COVID‑19 therapeutics.

Scripps Research
Scripps Research's ReFRAME drug repurposing collection. Image courtesy of Scripps Research.

ReFrame's collection includes 14,000 compounds, including medications already repurposed for disease treatment. Calibr created the collection in 2018 to address tropical diseases and other unmet medical needs.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.